On September 4, 2026, Sihuan Bio Technologies announced its plan to acquire 65.6146% of the shares in Zhongrun Pharmaceutical Co., Ltd. for cash, with a total transaction amount of 160 million yuan. Zhongrun Pharmaceutical is a medical and health service provider focused on the research, development, and supply of drugs for antiviral, emergency, oncology, and neurological diseases. This acquisition aims to strengthen Sihuan Bio Technologies’ market position in specialized pharmaceutical fields and enhance the synergy of its product lines. Currently, this transaction still requires relevant approval procedures and does not constitute a major asset restructuring.
On September 4, Sihuan Bio posted an announcement stating its intention to acquire 65.6146% of the shares in Zhongrun Pharmaceutical Co., Ltd. for cash, with a transaction value of 160 million yuan. Zhongrun Pharmaceutical is a medical and health service provider specializing in the research and development and supply of drugs for diseases such as antiviral, emergency rescue, tumor-related, and central nervous system disorders. This acquisition aims to strengthen Sihuan Bio’s presence in the field of specialty drugs and enhance the synergy of its product pipeline. The transaction still requires relevant approval procedures and does not involve significant asset restructuring.